✨ Free AI Report
Adaptimmune Therapeutics plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Adaptimmune Therapeutics plc
Company Research

Adaptimmune Therapeutics plc: Business Overview, Financials & Competitive Analysis

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company providing novel cell therapies primarily to cancer patients in the United States and the United Kingdom. The company develops TECELRA (famit...

Analyst-debate audio for Adaptimmune Therapeutics plc

AskCyborg analysts argue the bull and bear cases for Adaptimmune Therapeutics plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Cell therapy pioneer with FDA-approved product but facing existential market valuation crisis requiring strategic pivoting or...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Cell Therapy / Cancer Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Adaptimmune Therapeutics plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Adaptimmune Therapeutics plc Overview

Pro stress-test →

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company providing novel cell therapies primarily to cancer patients in the United States and the United Kingdom. The company develops TECELRA (famitresgene autoleucel), a genetically modified autologous T-cell immunotherapy for unresectable or metastatic synovial sarcoma, along with Lete-cel and ADP-5701 candidates in development.

Strategic Profile

Pro stress-test →

Adaptimmune is working to redefine the treatment of solid tumor cancers with cell therapies, using a proprietary platform to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates. The company has achieved commercial traction with TECELRA and strategic partnerships including a collaboration with Galápagos and alliance with MD Anderson Cancer Center.

Competitive Landscape

Pro stress-test →

Adaptimmune competes in the cell therapy and cancer immunotherapy space against companies developing TCR therapies and CAR-T approaches. Competitors include NexImmune and approximately 54 other similar-stage companies. The company has partnered with Galápagos and MD Anderson to strengthen competitive positioning.

Industry Context

Adaptimmune Therapeutics plc operates in Biopharmaceutical / Cell Therapy / Cancer Immunotherapy.

Key facts

Founded: 2008 · Headquarters: Abingdon, United Kingdom · Employees: 506 · Revenue: $178.03M (2024) · Market cap: $7.69M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Adaptimmune Therapeutics plc.

  • 2024 revenue reached $178.03 million, a 195% increase from prior year's $60.28 million.
  • Q2 2025 TECELRA sales of $11.1 million with 16 patients invoiced represented >150% growth versus Q1 2025.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025Announced definitive agreement for sale of TECELRA, lete-cel, afami-cel, and uza-cel therapies to US WorldMeds
  • May 2025Q1 2025 results showed TECELRA momentum with 10 patients apheresed and $4.0 million net sales
  • +1 moreTrack every material event for Adaptimmune Therapeutics plc as it happens. Explore monitoring →
Get alerted when Adaptimmune Therapeutics plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

TCR T-cell therapy platformDeveloping personalized cell therapy candidates for oncology→CAR-T and cellular immunotherapyCommercial-stage cell therapy for hematologic malignancies→TCR-based solid tumor therapyPersonalized neoantigen-based immunotherapy→

Compare Adaptimmune Therapeutics plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Adaptimmune Therapeutics plc operates in Biopharmaceutical / Cell Therapy / Cancer Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Cell Therapy / Cancer Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Adaptimmune Therapeutics plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Adaptimmune Therapeutics plc and its top competitor on Cyborg Score”
“What did Adaptimmune Therapeutics plc do this quarter?”
“Is Adaptimmune Therapeutics plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Adaptimmune Therapeutics plc do?+
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company providing novel cell therapies primarily to cancer patients in the United States and the United Kingdom. The company develops TECELRA (famit...
What is Adaptimmune Therapeutics plc's Cyborg Score?+
Adaptimmune Therapeutics plc has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Adaptimmune Therapeutics plc's main competitors?+
Named competitors include TCR T-cell therapy platform, CAR-T and cellular immunotherapy, TCR-based solid tumor therapy. The full competitive landscape is in the AskCyborg report.
How can I get the full Adaptimmune Therapeutics plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Adaptimmune Therapeutics plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Adaptimmune Therapeutics plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score